SCHEMBL10294875

SCHEMBL10294875

CCCCNc1nc(Nc2ncc(C)s2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MERTK Q12866 8/20 0.45
▸ FLT3 P36888 6/20 0.42
▸ TYRO3 Q06418 6/20 0.42
▸ GAS6 Q14393 5/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ RAB9A P51151 1/20 0.41
▸ AURKB Q96GD4 4/20 0.39
▸ AURKA O14965 4/20 0.39
▸ RIPK1 Q13546 2/20 0.39
▸ SRC P12931 2/20 0.39
▸ GSK3B P49841 1/20 0.39
▸ PLK4 O00444 2/20 0.38
▸ AURKC Q9UQB9 2/20 0.38
▸ AXL P30530 2/20 0.38
▸ BMPR1B O00238 1/20 0.38
▸ STK25 O00506 1/20 0.38
▸ RIOK3 O14730 1/20 0.38
▸ CHEK1 O14757 1/20 0.38
▸ GAK O14976 1/20 0.38
▸ MUSK O15146 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10295042 0.92 SMN1; SMN2 (0.43) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10294693 0.90 SMN1; SMN2 (0.40) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10294670 0.89 SMN1; SMN2 (0.41) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10294736 0.87 LCK (0.43) MERTKFLT3TYRO3SMN1; SMN2AURKB
SCHEMBL10294979 0.87 AURKA (0.39) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10295025 0.86 SMN1; SMN2 (0.45) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10294671 0.86 SMN1; SMN2 (0.48) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10294664 0.85 AURKB (0.47) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10294761 0.85 SMN1; SMN2 (0.46) MERTKFLT3TYRO3SMN1; SMN2RAB9A
SCHEMBL10294808 0.85 SMN1; SMN2 (0.47) MERTKFLT3TYRO3SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120172361-A1 TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-07-05 — — US disclosed
WO-2010144359-A1 TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS ABRAXIS BIOSCIENCE, LLC (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172361-A1 TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS CYP3A5, CYP11B2, ABCB1 MERTK 3314/4885FLT3 43/4885TYRO3 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback